Search form

MASAC Recommendation Regarding Reimbursement for Treatment of Acquired Hemophilia

PrintFriendly

Printer Friendly and PDF

MASAC Recommendation: 101

MASAC Recommendation Regarding Reimbursement for Treatment of Acquired Hemophilia

Date: 
June 10, 2000
  • It is well documented that persons with acquired hemophilia may require treatment with the same clotting factor concentrates that are used to treat persons with inherited hemophilia complicated by inhibitors. Failure to provide adequate reimbursement for these coagulation therapies may adversely impact patient care, morbidity, and mortality. Thus, the Medical and Scientific Advisory Council of the National Hemophilia Foundation recommends that reimbursement for clotting factor concentrates for persons with acquired hemophilia be the same as for persons with congenital hemophilia with inhibitors.